首页> 外文期刊>EBioMedicine >Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013
【24h】

Research Investments in Global Health: A Systematic Analysis of UK Infectious Disease Research Funding and Global Health Metrics, 1997-2013

机译:全球卫生领域的研究投资:1997-2013年英国传染病研究经费和全球卫生指标的系统分析

获取原文
           

摘要

Background: Infectious diseases account for a significant global burden of disease and substantial investment in research and development. This paper presents a systematic assessment of research investments awarded to UK institutions and global health metrics assessing disease burden. Methods: We systematically sourced research funding data awarded from public and philanthropic organisations between 1997 and 2013. We screened awards for relevance to infection and categorised data by type of science, disease area and specific pathogen. Investments were compared with mortality, disability-adjusted life years (DALYs) and years lived with disability (YLD) across three time points. Findings: Between 1997-2013, there were 7398 awards with a total investment of @$3.7 billion. An increase in research funding across 2011-2013 was observed for most disease areas, with notable exceptions being sexually transmitted infections and sepsis research where funding decreased. Most funding remains for pre-clinical research (@$2.2 billion, 59.4%). Relative to global mortality, DALYs and YLDs, acute hepatitis C, leishmaniasis and African trypanosomiasis received comparatively high levels of funding. Pneumonia, shigellosis, pertussis, cholera and syphilis were poorly funded across all health metrics. Tuberculosis (TB) consistently attracts relatively less funding than HIV and malaria. Interpretation: Most infections have received increases in research investment, alongside decreases in global burden of disease in 2013. The UK demonstrates research strengths in some neglected tropical diseases such as African trypanosomiasis and leishmaniasis, but syphilis, cholera, shigellosis and pneumonia remain poorly funded relative to their global burden. Acute hepatitis C appears well funded but the figures do not adequately take into account projected future chronic burdens for this condition. These findings can help to inform global policymakers on resource allocation for research investment.
机译:背景:传染病在全球造成了沉重的疾病负担,并在研发上投入了大量资金。本文对授予英国机构的研究投资和评估疾病负担的全球健康指标进行了系统评估。方法:我们系统地收集了1997年至2013年间从公共和慈善组织获得的研究经费数据。我们筛选了与感染相关的奖项,并按科学类型,疾病领域和特定病原体对数据进行了分类。将投资与三个时间点的死亡率,伤残调整生命年(DALYs)和伤残寿命年(YLD)进行比较。调查结果:在1997年至2013年间,共颁发了7398个奖项,总投资额为37亿美元。在大多数疾病领域,2011-2013年间的研究经费有所增加,但值得注意的例外是性传播感染和败血症研究,经费有所减少。临床前研究资金最多(@ 22亿美元,占59.4%)。相对于全球死亡率,DALYs和YLDs,急性丙型肝炎,利什曼病和非洲锥虫病获得的资金相对较高。在所有健康指标中,肺炎,志贺氏菌病,百日咳,霍乱和梅毒的资金不足。与艾滋病毒和疟疾相比,结核病一直吸引的资金相对较少。解释:2013年,大多数感染的研究投资有所增加,全球疾病负担有所减轻。英国在一些被忽视的热带疾病(如非洲锥虫病和利什曼病)方面显示出研究优势,但梅毒,霍乱,志贺氏菌病和肺炎的资金相对不足他们的全球负担。急性丙型肝炎似乎有充足的资金,但数字并未充分考虑到这种情况下预计的未来慢性负担。这些发现可以帮助全球决策者了解研究投资的资源分配情况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号